Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Daiichi Sankyo
Cipla
US Army
Moodys
Cantor Fitzgerald
UBS
Healthtrust
Teva

Generated: May 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,872,390

« Back to Dashboard

Which drugs does patent 6,872,390 protect, and when does it expire?

Patent 6,872,390 protects ORAVERSE and is included in one NDA.

This patent has fifteen patent family members in fourteen countries.
Summary for Patent: 6,872,390
Title: Local anesthetic methods and kits
Abstract:Methods of reversing local anesthesia are disclosed. The methods comprise administering a local anesthetic and alpha adrenergic receptor agonist to induce local anesthesia followed by reversing anesthesia with a low dose of an alpha adrenergic receptor antagonist. Also disclosed are kits comprising a local anesthetic, an alpha adrenergic receptor agonist and a low dose of an alpha adrenergic receptor antagonist.
Inventor(s): Weber; Eckard (San Diego, CA), Katz; Howard I. (La Jolla, CA)
Assignee: Novalar Pharmaceuticals, Inc. (DE)
Application Number:10/155,020
Patent Claim Types:
see list of patent claims
Formulation;

Drugs Protected by US Patent 6,872,390

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Septodont Holding ORAVERSE phentolamine mesylate INJECTABLE;INJECTION 022159-001 May 9, 2008 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 6,872,390

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,261,889 Local anesthetic methods and kits ➤ Sign Up
6,432,401 Local anesthetic methods and kits ➤ Sign Up
6,764,678 Local anesthetic methods and kits ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Baxter
Fish and Richardson
Cipla
Cantor Fitzgerald
Farmers Insurance
McKesson
Queensland Health
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.